Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary biliary cirrhosis.

Jayant A Talwalkar1, Keith D Lindor

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.

Lancet (London, England)
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?

Hepatology (Baltimore, Md.)·2025
Same author

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

JHEP reports : innovation in hepatology·2023
Same author

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.

Liver international : official journal of the International Association for the Study of the Liver·2023
Same author

Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2023
Same author

Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

The American journal of gastroenterology·2023
Same author

Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe.

European journal of gastroenterology & hepatology·2022
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Primary biliary cirrhosis is a chronic liver disease causing bile duct destruction and liver failure. Early diagnosis and ursodeoxycholic acid treatment can halt progression, though complications like fatigue remain untreated.

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease.
  • Histologically, it involves non-suppurative destruction of interlobular bile ducts, leading to fibrosis, cirrhosis, and liver failure.
  • The exact cause is unknown, but immune system dysregulation and genetic factors are implicated.

Purpose of the Study:

  • To summarize the understanding of primary biliary cirrhosis (PBC).
  • To highlight diagnostic markers and current treatment efficacy.
  • To identify unmet needs in managing PBC complications.

Main Methods:

  • Review of existing literature on primary biliary cirrhosis.
  • Analysis of diagnostic criteria, including serological markers like antimitochondrial antibody.

Related Experiment Videos

  • Evaluation of treatment outcomes with ursodeoxycholic acid.
  • Discussion of disease progression and complications.

    • Main Results:

    • Antimitochondrial antibody presence is nearly diagnostic for PBC.
    • Ursodeoxycholic acid treatment can halt disease progression and improve survival.
    • Effective treatments for fatigue and metabolic bone disease in PBC patients are lacking.
    • Mathematical models can predict PBC's natural history.

    Conclusions:

    • Primary biliary cirrhosis is a significant cause of liver transplantation.
    • While ursodeoxycholic acid is effective for disease progression, managing complications requires further research.
    • Understanding PBC's pathogenesis is crucial for developing novel therapies.